Prognostic and Diagnostic Value of Serial Biomarker Measurements, Echocardiographic Techniques and Cardiopulmonary Function Tests in Patients With Chronic Heart Failure.

Shanghai Jiao Tong University School of Medicine1 site in 1 country1,000 target enrollmentDecember 2015

ConditionsChronic Heart Failure

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Heart Failure
Sponsor: Shanghai Jiao Tong University School of Medicine
Enrollment: 1000
Locations: 1
Primary Endpoint: cardiovascular mortality
Status: Recruiting
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study aims to investigate whether disease progression in patients with chronic heart failure (CHF) can be assessed by new biomarkers, and determine their diagnostic value. The study also intends to describe comparison of echocardiography with cardiopulmonary function test in CHF patients, and relating these cardiac functional parameters to clinical outcome.

Registry

clinicaltrials.gov

Start Date

December 2015

End Date

December 2025

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Shanghai Jiao Tong University School of Medicine

Responsible Party

Principal Investigator

Zhang Qi, MD

Shanghai Jiao Tong University School of Medicine

Eligibility Criteria

Inclusion Criteria

•Age ≥18 years
•with symptoms and signs in NYHA Ⅱ\~Ⅳ
•with cardiac structural changes confirmed by echocardiography

Exclusion Criteria

•with other severe diseases combined and will be alive for less than 12 months
•hard to participate in the investigation or accept the follow-up visits
•pregnant or lactating women
•during the acute phase of ST-elevation acute myocardial infarction, stroke, severe infection and other critical conditions

Outcomes

Primary Outcomes

cardiovascular mortality

Time Frame: 10 years

main adverse cardiovascular and cerebrovascular events, MACCE

Time Frame: 10 years

MACCE includes all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, target lesion revascularization and HF rehospitalization